| ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway B Chu, N Kon, D Chen, T Li, T Liu, L Jiang, S Song, O Tavana, W Gu Nature cell biology 21 (5), 579-591, 2019 | 616 | 2019 |
| p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer JG Jackson, V Pant, Q Li, LL Chang, A Quintás-Cardama, D Garza, ... Cancer cell 21 (6), 793-806, 2012 | 352 | 2012 |
| The deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7A11 T Liu, L Jiang, O Tavana, W Gu Cancer research 79 (8), 1913-1924, 2019 | 332 | 2019 |
| p53 modifications: exquisite decorations of the powerful guardian Y Liu, O Tavana, W Gu Journal of molecular cell biology 11 (7), 564-577, 2019 | 331 | 2019 |
| NRF2 is a major target of ARF in p53-independent tumor suppression D Chen, O Tavana, B Chu, L Erber, Y Chen, R Baer, W Gu Molecular cell 68 (1), 224-232. e4, 2017 | 274 | 2017 |
| HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma O Tavana, D Li, C Dai, G Lopez, D Banerjee, N Kon, C Chen, A Califano, ... Nature medicine 22 (10), 1180-1186, 2016 | 205 | 2016 |
| Modulation of the p53/MDM2 interplay by HAUSP inhibitors O Tavana, W Gu Journal of molecular cell biology 9 (1), 45-52, 2017 | 93 | 2017 |
| Absence of p53-dependent apoptosis leads to UV radiation hypersensitivity, enhanced immunosuppression and cellular senescence O Tavana, CL Benjamin, N Puebla-Osorio, M Sang, SE Ullrich, ... Cell cycle 9 (16), 3348-3356, 2010 | 74 | 2010 |
| Absence of p53-dependent apoptosis combined with nonhomologous end-joining deficiency leads to a severe diabetic phenotype in mice O Tavana, N Puebla-Osorio, M Sang, C Zhu Diabetes 59 (1), 135-142, 2010 | 67 | 2010 |
| The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets Z Hu, J Yuan, M Long, J Jiang, Y Zhang, T Zhang, M Xu, Y Fan, JL Tanyi, ... Nature cancer 2 (12), 1406-1422, 2021 | 54 | 2021 |
| AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia SB Balachander, SW Criscione, KF Byth, J Cidado, A Adam, P Lewis, ... Clinical Cancer Research 26 (24), 6535-6549, 2020 | 50 | 2020 |
| Discovery of proteolysis-targeting chimera molecules that selectively degrade the IRAK3 pseudokinase SL Degorce, O Tavana, E Banks, C Crafter, L Gingipalli, D Kouvchinov, ... Journal of Medicinal Chemistry 63 (18), 10460-10473, 2020 | 43 | 2020 |
| ATM and p53 are essential in the cell-cycle containment of DNA breaks during V (D) J recombination in vivo ME Dujka, N Puebla-Osorio, O Tavana, M Sang, C Zhu Oncogene 29 (7), 957-965, 2010 | 41 | 2010 |
| Too many breaks (brakes): pancreatic β-cell senescence leads to diabetes O Tavana, C Zhu Cell Cycle 10 (15), 2471-2484, 2011 | 38 | 2011 |
| Independent functions of DNMT1 and USP7 at replication foci O Yarychkivska, O Tavana, W Gu, TH Bestor Epigenetics & Chromatin 11, 1-9, 2018 | 27 | 2018 |
| Deciphering the acetylation code of p53 in transcription regulation and tumor suppression Z Xia, N Kon, AP Gu, O Tavana, W Gu Oncogene 41 (22), 3039-3050, 2022 | 24 | 2022 |
| The Hunger Games: p53 regulates metabolism upon serine starvation O Tavana, W Gu Cell metabolism 17 (2), 159-161, 2013 | 22 | 2013 |
| Peli1 modulates the subcellular localization and activity of Mdmx D Li, O Tavana, SC Sun, W Gu Cancer research 78 (11), 2897-2910, 2018 | 21 | 2018 |
| Targeting HAUSP in both p53 wildtype and p53-mutant tumors O Tavana, H Sun, W Gu Cell Cycle 17 (7), 823-828, 2018 | 21 | 2018 |
| Systematic illumination of druggable genes in cancer genomes J Jiang, J Yuan, Z Hu, Y Zhang, T Zhang, M Xu, M Long, Y Fan, JL Tanyi, ... Cell reports 38 (8), 2022 | 19 | 2022 |
